Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial

Background: COVID-19 convalescent plasma (CCP) is an important antiviral option for selected patients with COVID-19. Materials and Methods: In this open-label, phase 2, clinical trial conducted from 30 April 2020 till 10 May 2021 in the Republic of North Macedonia, we evaluated the efficacy and safe...

Full description

Bibliographic Details
Main Authors: Rada M. Grubovic Rastvorceva, Sedula Useini, Milena Stevanovic, Ilir Demiri, Elena Petkovic, Massimo Franchini, Daniele Focosi
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Life
Subjects:
convalescent plasma
COVID-19
SARS-CoV-2
Online Access:https://www.mdpi.com/2075-1729/12/10/1565

Internet

https://www.mdpi.com/2075-1729/12/10/1565

Similar Items